2024
Real-World Healthcare Costs Among Patients With Chronic Lymphocytic Leukemia Receiving First-Line Treatment With Venetoclax + Obinutuzumab Versus Bruton Tyrosine Kinase Inhibitors
Ravelo A, Patel A, To T, Li S, Huntington S. Real-World Healthcare Costs Among Patients With Chronic Lymphocytic Leukemia Receiving First-Line Treatment With Venetoclax + Obinutuzumab Versus Bruton Tyrosine Kinase Inhibitors. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s180. DOI: 10.1016/s2152-2650(24)00569-x.Peer-Reviewed Original ResearchCLL-144 Real-World Healthcare Costs Among Patients With Chronic Lymphocytic Leukemia Receiving First-Line Treatment With Venetoclax + Obinutuzumab Versus Bruton Tyrosine Kinase Inhibitors
Ravelo A, Patel A, To T, Li S, Huntington S. CLL-144 Real-World Healthcare Costs Among Patients With Chronic Lymphocytic Leukemia Receiving First-Line Treatment With Venetoclax + Obinutuzumab Versus Bruton Tyrosine Kinase Inhibitors. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s345. DOI: 10.1016/s2152-2650(24)01263-1.Peer-Reviewed Original ResearchPer-patient per-monthPer-patient per-month costsChronic lymphocytic leukemiaBruton tyrosine kinase inhibitorFirst-line treatmentTyrosine kinase inhibitorsLymphocytic leukemiaMonths 0Kinase inhibitorsHealthcare costsCLL/small lymphocytic lymphomaFixed-duration treatmentFirst-line therapyOff-treatment periodMonths post-indexMonths pre-indexRetrospective observational studyClinical trial enrollmentUS health planCommercially insured patientsLymphocytic lymphomaPrimary cancerFirst-linePost-indexIbrutinibReal-world comparison of health care costs of venetoclax-obinutuzumab vs Bruton's tyrosine kinase inhibitor use among US Medicare beneficiaries with chronic lymphocytic leukemia in the frontline setting.
Huntington S, Manzoor B, Jawaid D, Puckett J, Emechebe N, Ravelo A, Kamal-Bahl S, Doshi J. Real-world comparison of health care costs of venetoclax-obinutuzumab vs Bruton's tyrosine kinase inhibitor use among US Medicare beneficiaries with chronic lymphocytic leukemia in the frontline setting. Journal Of Managed Care & Specialty Pharmacy 2024, 30: 1106-1116. PMID: 39046941, PMCID: PMC11424914, DOI: 10.18553/jmcp.2024.24049.Peer-Reviewed Original ResearchChronic lymphocytic leukemiaMonths 0Frontline settingSample of older US adultsMedicare beneficiariesLymphocytic leukemiaFee-for-service Medicare beneficiariesTreatment periodStudy of older adultsTyrosine kinase inhibitor useOlder US adultsBruton tyrosine kinase inhibitorFixed-duration therapyUS Medicare beneficiariesFee-for-serviceMonthly costTyrosine kinase inhibitorsHealth care costsMedicare Part ABcl-2 inhibitorsMultivariate general linear modelMonthly total costsTotal monthly costsPrescription drug costsComparison of health care costsReal-world patterns and sequences of targeted therapy use in chronic lymphocytic leukemia and small lymphocytic lymphoma in the United States: a longitudinal study
Huntington S, Cheng W, Sarpong E, Leng S, Farooqui M, Agu U, Catillon M, Lejeune D, Downes N, Matay L, Duh M, De Nigris E. Real-world patterns and sequences of targeted therapy use in chronic lymphocytic leukemia and small lymphocytic lymphoma in the United States: a longitudinal study. Leukemia & Lymphoma 2024, 65: 932-942. PMID: 38696747, DOI: 10.1080/10428194.2024.2331631.Peer-Reviewed Original ResearchSequential targeted therapyLymphocytic lymphomaTherapy useB-cell lymphoma 2 inhibitorChronic lymphocytic leukemia/small lymphocytic lymphomaBruton tyrosine kinase inhibitorTargeted therapy useSmall lymphocytic lymphomaChronic lymphocytic leukemiaTyrosine kinase inhibitorsProportion of patientsClaims-based studyFirst-lineLymphocytic leukemiaTargeted therapyClinical outcomesB cellsKinase inhibitorsTreatment sequenceReal-world patternsTherapyCLL/SLLBTKiCD20LymphomaReal‐world analysis of adverse event rates after initiation of ibrutinib among Medicare beneficiaries with chronic lymphocytic leukemia
Huntington S, de Nigris E, Puckett J, Kamal‐Bahl S, Farooqui M, Ryland K, Sarpong E, Leng S, Yang X, Doshi J. Real‐world analysis of adverse event rates after initiation of ibrutinib among Medicare beneficiaries with chronic lymphocytic leukemia. Cancer Medicine 2024, 13: e6953. PMID: 38348963, PMCID: PMC10832339, DOI: 10.1002/cam4.6953.Peer-Reviewed Original ResearchConceptsChronic lymphocytic leukemiaRate of adverse eventsIncidence rate of adverse eventsAdverse eventsPatient-monthsLymphocytic leukemiaIncidence ratePatients treated with ibrutinibTreatment of chronic lymphocytic leukemiaStandard-of-care therapyNon-discontinuationInitiation of ibrutinibBTK inhibitor ibrutinibAdverse event ratesPotential side effectsInhibitor ibrutinibMedicare beneficiariesReal-world analysisAtrial fibrillationFollow-upIbrutinibSide effectsReal-world outcomesEvent ratesLeukemiaRacial Disparities in Telemedicine Uptake during the COVID-19 Pandemic among Patients with Hematologic Malignancies in the United States
Neparidze N, W. Lau K, Wang X, Huntington S, Jamy O, S. Calip G, Shah H, M. Stephens D, Miksad R, Parikh R, Takvorian S, Goyal G, Seymour E. Racial Disparities in Telemedicine Uptake during the COVID-19 Pandemic among Patients with Hematologic Malignancies in the United States. Medical Research Archives 2024, 12 DOI: 10.18103/mra.v12i2.5164.Peer-Reviewed Original ResearchAcute myelogenous leukemiaMantle cell lymphomaChronic lymphocytic leukemiaDiffuse large B-cell lymphomaFollicular lymphomaMultiple myelomaWhite patientsBlack patientsCell lymphomaHematologic malignanciesLymphocytic leukemiaTreatment categoriesElectronic health record (EHR)-derived de-identified databaseDiagnosis of acute myelogenous leukemiaLarge B-cell lymphomaTelemedicine uptakeActive patientsLines of therapyB-cell lymphomaMonthly visit ratesMyeloma patientsVisit ratesAnalyzed patientsMyelogenous leukemiaLymphoma
2023
Real-World Comparison of Healthcare Costs of Venetoclax-Obinutuzumab Vs. Btki Use Among Elderly U.S. Medicare Beneficiaries with Chronic Lymphocytic Leukemia in the Front-Line (1L) Setting
Manzoor B, Huntington S, Jawaid D, Puckett J, Emechebe N, Ravelo A, Kamal-Bahl S, Doshi J. Real-World Comparison of Healthcare Costs of Venetoclax-Obinutuzumab Vs. Btki Use Among Elderly U.S. Medicare Beneficiaries with Chronic Lymphocytic Leukemia in the Front-Line (1L) Setting. Blood 2023, 142: 5085. DOI: 10.1182/blood-2023-177939.Peer-Reviewed Original ResearchChronic lymphocytic leukemiaPost-index periodU.S. Medicare beneficiariesBTK inhibitorsHealth care costsMedicare beneficiariesTreatment periodIndex dateMonth 13Months 0Prescription coverageLymphocytic leukemiaHealthcare costsCare costsMonths post-index periodDiagnosis of CLLMonthly health care costsMonthly costCause total costsFixed-duration treatmentPre-index periodPrior CLL treatmentTreatment-free remissionBCL-2 inhibitor venetoclaxFront-line settingIbrutinib discontinuation and associated factors in a real-world national sample of elderly Medicare beneficiaries with chronic lymphocytic leukemia
Huntington S, de Nigris E, Puckett J, Kamal-Bahl S, Farooqui M, Ryland K, Sarpong E, Leng S, Yang X, Doshi J. Ibrutinib discontinuation and associated factors in a real-world national sample of elderly Medicare beneficiaries with chronic lymphocytic leukemia. Leukemia & Lymphoma 2023, 64: 2286-2295. PMID: 37870435, DOI: 10.1080/10428194.2023.2256911.Peer-Reviewed Original ResearchConceptsChronic lymphocytic leukemiaIbrutinib discontinuationLymphocytic leukemiaHalf of patientsMonths of initiationElderly Medicare beneficiariesLarge unmet needPart D low-income subsidyLow-income subsidyCardiovascular comorbiditiesElderly patientsReal-world practiceIbrutinib treatmentLymphocytic lymphomaAdvanced ageClinical trialsMedical CenterMedicare claimsDiscontinuationHigh riskMedicare beneficiariesUnmet needPatientsLeukemiaTwo-thirdsReal-world adherence and discontinuation among Medicare beneficiaries initiating venetoclax vs. BTKis in relapsed/refractory chronic lymphocytic leukemia
Huntington S, Manzoor B, Puckett J, Kamal-Bahl S, Alhasani H, Ravelo A, Jawaid D, Doshi J. Real-world adherence and discontinuation among Medicare beneficiaries initiating venetoclax vs. BTKis in relapsed/refractory chronic lymphocytic leukemia. Leukemia & Lymphoma 2023, 64: 2316-2323. PMID: 37732602, DOI: 10.1080/10428194.2023.2255326.Peer-Reviewed Original ResearchConceptsChronic lymphocytic leukemiaReal-world adherenceRefractory chronic lymphocytic leukemiaTyrosine kinase inhibitorsLymphocytic leukemiaB-cell lymphoma-2 inhibitorBruton tyrosine kinase inhibitorsNovel oral agentsClinical trial dataOral agentsClinical characteristicsElderly patientsTreatment landscapeTreatment initiationReal-world findingsHigh adherenceMedicare beneficiariesLower discontinuationTrial dataDiscontinuationPatientsOlder adultsKinase inhibitorsAdherenceLeukemiaThe COVID-19 Pandemic and In-Person Visit Rate Disruptions Among Patients With Hematologic Neoplasms in the US in 2020 to 2021
Goyal G, Lau K, Wang X, Davidoff A, Huntington S, Jamy O, Calip G, Shah H, Stephens D, Miksad R, Parikh R, Takvorian S, Neparidze N, Seymour E. The COVID-19 Pandemic and In-Person Visit Rate Disruptions Among Patients With Hematologic Neoplasms in the US in 2020 to 2021. JAMA Network Open 2023, 6: e2316642. PMID: 37273206, PMCID: PMC10242428, DOI: 10.1001/jamanetworkopen.2023.16642.Peer-Reviewed Original ResearchConceptsEarly pandemic monthsOral therapyOutpatient infusionsChronic lymphocytic leukemiaHematologic neoplasmsVisit ratesTelemedicine useCohort studyPandemic monthsLymphocytic leukemiaRetrospective observational cohort studyData cutoff datePerson medical careSubsequent cancer outcomesHalf of patientsObservational cohort studyMantle cell lymphomaCOVID-19COVID-19 pandemicNon-Hispanic whitesMedian ageActive treatmentCancer outcomesMultiple myelomaActive patientsEE158 Healthcare Resource Utilization and Costs Among Medicare Beneficiaries Initiating Venetoclax Vs. Btkis for Relapsed/Refractory Chronic Lymphocytic Leukemia: A Real-World Study
Huntington S, Manzoor B, Jawaid D, Puckett J, Alhasani H, Ravelo A, Kamal-Bahl S, Emechebe N, Doshi J. EE158 Healthcare Resource Utilization and Costs Among Medicare Beneficiaries Initiating Venetoclax Vs. Btkis for Relapsed/Refractory Chronic Lymphocytic Leukemia: A Real-World Study. Value In Health 2023, 26: s88-s89. DOI: 10.1016/j.jval.2023.03.461.Peer-Reviewed Original Research
2022
Real-World Treatment Patterns and Outcomes after Ibrutinib Discontinuation Among Elderly Medicare Beneficiaries with Chronic Lymphocytic Leukemia: An Observational Study
Huntington S, De Nigris E, Puckett J, Kamal-Bahl S, Farooqui M, Ryland K, Sarpong E, Yang X, Doshi J. Real-World Treatment Patterns and Outcomes after Ibrutinib Discontinuation Among Elderly Medicare Beneficiaries with Chronic Lymphocytic Leukemia: An Observational Study. Blood 2022, 140: 7939-7940. DOI: 10.1182/blood-2022-155903.Peer-Reviewed Original ResearchPoster: CLL-410 Adherence and Discontinuation Among Medicare Beneficiaries Initiating Venetoclax versus BTKis for Relapsed/Refractory Chronic Lymphocytic Leukemia
Huntington S, Manzoor B, Puckett J, Kamal-Bahl S, Alhasani H, Ravelo A, Fuldeore M, Doshi J. Poster: CLL-410 Adherence and Discontinuation Among Medicare Beneficiaries Initiating Venetoclax versus BTKis for Relapsed/Refractory Chronic Lymphocytic Leukemia. Clinical Lymphoma Myeloma & Leukemia 2022, 22: s143. DOI: 10.1016/s2152-2650(22)00867-9.Peer-Reviewed Original ResearchCLL-410 Adherence and Discontinuation Among Medicare Beneficiaries Initiating Venetoclax versus BTKis for Relapsed/Refractory Chronic Lymphocytic Leukemia
Huntington S, Manzoor B, Puckett J, Kamal-Bahl S, Alhasani H, Ravelo A, Fuldeore M, Doshi J. CLL-410 Adherence and Discontinuation Among Medicare Beneficiaries Initiating Venetoclax versus BTKis for Relapsed/Refractory Chronic Lymphocytic Leukemia. Clinical Lymphoma Myeloma & Leukemia 2022, 22: s277-s278. DOI: 10.1016/s2152-2650(22)01345-3.Peer-Reviewed Original ResearchPoor clinical characteristicsClinical characteristicsReal-world studyUnadjusted ratesMedicare beneficiariesRelapsed/Refractory Chronic Lymphocytic LeukemiaRefractory chronic lymphocytic leukemiaChronic lymphocytic leukemia treatmentRetrospective claims-based studyOlder adultsPost-index periodReal-world adherenceHigher unadjusted ratesClaims-based studyService Medicare beneficiariesChronic lymphocytic leukemiaNational Medicare dataClinical trial dataR CLLRefractory CLLTreatment patternsAdjusted outcomesTreatment outcomesHigh adherenceLymphocytic leukemia
2019
Utilization and Early Discontinuation of First-Line Ibrutinib for Patients with Chronic Lymphocytic Leukemia Treated in the Community Oncology Setting in the United States
Huntington S, Soulos P, Barr P, Jacobs R, Lansigan F, Odejide O, Schwartzberg L, Davidoff A, Gross C. Utilization and Early Discontinuation of First-Line Ibrutinib for Patients with Chronic Lymphocytic Leukemia Treated in the Community Oncology Setting in the United States. Blood 2019, 134: 797. DOI: 10.1182/blood-2019-122054.Peer-Reviewed Original ResearchFirst-line settingChronic lymphocytic leukemiaFlatiron Health databaseECOG performance statusFirst-line treatmentEarly discontinuationMultivariable logistic regressionPerformance statusIbrutinib discontinuationSpeakers bureauClinical trialsCLL diagnosisCLL therapyLymphocytic leukemiaHealth databasesLogistic regressionBruton tyrosine kinase inhibitorsFirst-line ibrutinibUse of ibrutinibWorse performance statusPoor performance statusRetrospective cohort studyCommunity oncology settingClinical decision support toolCommunity oncology practices
2018
Real-world treatment and outcomes among older adults with chronic lymphocytic leukemia before the novel agents era
Mato A, Jahnke J, Li P, Mehra M, Ladage VP, Mahler M, Huntington S, Doshi JA. Real-world treatment and outcomes among older adults with chronic lymphocytic leukemia before the novel agents era. Haematologica 2018, 103: e462-e465. PMID: 29700170, PMCID: PMC6165790, DOI: 10.3324/haematol.2017.185868.Peer-Reviewed Original ResearchConceptsNovel agent eraReal-world treatmentChronic lymphocytic leukemiaAgent eraLymphocytic leukemiaOlder adults
2016
Characterization of Real World Survival Outcomes Among Older Adults with Chronic Lymphocytic Leukemia Receiving Second Line Treatment in the Pre Novel-Agents Era: An Analysis of the 2007-2013 SEER-Medicare Database
Mato A, Jahnke J, Li P, Mehra M, Ladage V, Mahler M, Fanning M, Doshi J, Huntington S. Characterization of Real World Survival Outcomes Among Older Adults with Chronic Lymphocytic Leukemia Receiving Second Line Treatment in the Pre Novel-Agents Era: An Analysis of the 2007-2013 SEER-Medicare Database. Blood 2016, 128: 4790. DOI: 10.1182/blood.v128.22.4790.4790.Peer-Reviewed Original ResearchSecond-line treatmentChronic lymphocytic leukemiaSecond-line cohortSecond-line therapyOverall survivalLine treatmentInitial therapyClinical trialsLine therapyInitial treatmentCLL treatmentSurvival outcomesCLL patientsOlder adultsNovel agentsCLL outcomeLymphocytic leukemiaMedicare feeCommon second-line treatmentReal-world survival outcomesRecent landmark clinical trialsRelapsed chronic lymphocytic leukemiaMultivariate Cox regression modelingSecond lineAdvisory CommitteeCharacterization of Real World Treatment Patterns and Outcomes Among Older Adults with Chronic Lymphocytic Leukemia in the Pre Novel-Agents Era: An Analysis of the 2007-2013 SEER-Medicare Database
Mato A, Jahnke J, Li P, Mehra M, Ladage V, Mahler M, Huntington S, Doshi J. Characterization of Real World Treatment Patterns and Outcomes Among Older Adults with Chronic Lymphocytic Leukemia in the Pre Novel-Agents Era: An Analysis of the 2007-2013 SEER-Medicare Database. Blood 2016, 128: 4773. DOI: 10.1182/blood.v128.22.4773.4773.Peer-Reviewed Original ResearchChronic lymphocytic leukemiaOlder CLL patientsOverall survivalTreatment initiationCox regressionCLL patientsClinical trialsFirst treatmentNovel agentsChlorambucil monotherapyOlder adultsLymphocytic leukemiaMedicare feeClinical practiceLow-income subsidy statusReal-world treatment patternsRecent landmark clinical trialsCLL/SLL patientsLogistic regressionOlder individualsAdvisory CommitteeGilead SciencesReal-world outcome dataAnemia/thrombocytopeniaApproval of ibrutinib
2015
Evolution to plasmablastic lymphoma evades CD19‐directed chimeric antigen receptor T cells
Evans AG, Rothberg PG, Burack WR, Huntington SF, Porter DL, Friedberg JW, Liesveld JL. Evolution to plasmablastic lymphoma evades CD19‐directed chimeric antigen receptor T cells. British Journal Of Haematology 2015, 171: 205-209. PMID: 26084925, DOI: 10.1111/bjh.13562.Peer-Reviewed Original ResearchT cellsChimeric antigen receptor T cellsRefractory chronic lymphocytic leukemiaAntigen receptor T cellsCAR T-cell therapyPre-plasma cellsReceptor T cellsChimeric antigen receptorChronic lymphocytic leukemiaMolecular genetic evaluationPlasmablastic lymphomaRichter transformationMature lymphomasRoutine markersLymphocytic leukemiaSingle patientNormal cellular counterpartsCell therapyAntigen receptorLymphoid differentiationCD19PatientsLymphomaCellsCellular counterparts